跳至主要内容

Medicilon's Immuno-oncology Models Evaluation Platform

 Immuno-oncology Model

In recent years, tumor immunotherapy has become the core of cancer treatment research. With innovation as the driving force, Medicilon has vigorously developed a tumor immunity (Immuno-oncology) drug efficacy evaluation research platform. Currently, CAR-T, TCR-T, CAR-NK, Oncolytic Virus, antibodies (monoclonal antibodies, double antibodies, polyclonal antibodies, etc.), siRNA, AAV, and other immunotherapy models and methods for evaluating the efficacy of immunotherapy, empower the research process of innovative therapies and protect health!

Syngenic Models

The homologous tumor transplantation model tests the ability of model animals to use their perfect immune system to fight cancer and the therapeutic effect of immunotherapy.The choices we offer you are:

Types of Syngenic Models
Types of Syngenic Models

Classification of immune cells in model blood by flow cytometry

PBMC Humanized Models

The humanized tumor mouse model of a partially reorganized human immune system is particularly effective for short-term or high-throughput research.

The types of models currently available for Medicilon are:

PBMC Humanized Models

Tumor growth and drug efficacy evaluation of PBMC humanized mouse lymphoma transplantation model.

PBMC humanized mouse lymphoma transplantation model

CD34+ HSC Humanized Models

Humanized mice transplanted with CD34+ human umbilical cord blood cells to reconstruct the human hematopoietic system are colonized in the mouse bone marrow and continuously and stably produce various human hematopoietic cells and immune cells and use the human immune system to evaluate multiple immunotherapy.

Medicilon’s currently available models are:

CD34+ HSC Humanized Models


Orthotopic Model

The xenogeneic orthotopic tumor transplantation model can fully consider the interaction of tumor cells and the organ microenvironment between the surrounding stroma and monitor tumor growth when evaluating drug efficacy.

Medicilon will break the barriers of experimentation and technology for you. At present, it has mature orthotopic transplantation technology, including orthotopic brain transplantation, orthotopic liver transplantation, orthotopic lung transplantation, orthotopic transplantation of tibia marrow cavity, orthotopic intravesical transplantation Transplant, etc.

Orthotopic brain transplantation

Orthotopic brain transplantation

Lung metastasis model

Lung metastasis model

Tibia bone marrow cavity orthotopic transplantation

Tibia bone marrow cavity orthotopic transplantation

Orthotopic ovarian cancer transplantation

Orthotopic ovarian cancer transplantation

PDX Models

The human tumor transplantation model PDX retains the characteristics of the patient’s tumor tissue and is more clinically relevant. It can establish an ideal tumor immunotherapy evaluation model combined with humanized mice. Medicilon has now developed:

Medicilon’s PDX model research includes molecular-level genotyping and tumor model pharmacological efficacy evaluation services, providing a highly predictive model for clinical efficacy study.

contact us
Email: marketing@medicilon.com
Tel: +86 (21) 5859-1500

评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

What is Toxicokinetics?

Toxicokinetics  is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms  toxicokinetics ,  pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...